AtriCure delivered its first clean quarter of GAAP profitability since going public in 2005, and the print said two things at once. The first: revenue accelerated, with $153.6 million up 12.8% year over year and U.S. growth of 13.6% - driven by a 27.8% surge in the post-operative pain franchise and double-digit growth in AtriClip, the left-atrial-appendage (LAA) management platform that now has more than 750,000 patients treated cumulatively. The second: operating leverage showed up at scale. Gross margin expanded 270 basis points to 77.2%, R&D fell nearly 10% as a deferred 2025 milestone rolled off, and adjusted EBITDA of $27.3 million was 17.8% of revenue - a 650-basis-point margin expansion that took the quarter's non-GAAP earnings from $0.02 a year ago to $0.18 today, on the same diluted share count.
The quarter's two working pieces are not the only things that matter, though. Management raised the full-year guidance for the second consecutive report, and raised it materially: full-year 2026 adjusted EBITDA is now $85–$89 million, up from $80–$82 million at the Q1 call, with adjusted EPS now $0.24–$0.32 versus the $0.00–$0.04 range management gave eight weeks ago. The high end of the new range is more than seven times the high end of the prior one. At a reference price of $43.69 - within a dollar of a fresh 52-week high touched one day earlier, August 13 - the market has clearly priced in some of the guide-up. The investor's question is no longer "can AtriCure turn profitable," but "how durable is this profitability, and what does the company do for an encore in 2027." The structural competitive story - pulsed-field ablation catheters are still eroding the minimally invasive surgical ablation business, down 23.1% in the quarter - is real and continues; the PFA-driven erosion is the single thing the next eight quarters have to absorb.